Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Geminid meteors streak under green sky | Space photo of the day for Dec. 19, 2025 - 2Heavenly Pastry Confrontation: Pick Your #1 Sweet Treat!
- 3'Senseless violence' erupts at Christmas tree lighting; 4 injured
- 4Building an Individual Brand: Illustrations from Powerhouses
- 5Police break up illegal chicken slaughter in Germany
- Supercharge Your Remote Work Arrangement with These Game-Changing Instruments
- Unsold Rams May Be Less expensive Than You Suspect
- Purdue Pharma's deal means money for some victims, end of Purdue company name. Here's what to know
- Vaccine exemptions for religious or personal beliefs are rising across the U.S.
- Ukrainian Army Converts E38 BMW 7-Series Into Multiple Rocket Launch Platform
- Becoming amazing at Systems administration: Individual and Expert Tips
- 6 Top of the line Lodgings All over The Planet, Which One Do You Concur With
- Early Thanksgiving week forecast: Where Americans can expect cold, rain and snow for the holiday
- Cognizant Couture d: A Survey of \Moral Decisions and Sharp Looks\ Maintainable Style
